Marshall Wace, LLP Kura Oncology, Inc. Transaction History

Marshall Wace, LLP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$17.53 - $22.98 $460,460 - $603,615	26,267 New	26,267 $540,000
Q2 2023 Aug 14, 2023	BUY	$9.62 - $13.99 $769,638 - $1.12 Million	80,004 New	80,004 $846,000
Q1 2021 May 17, 2021	SELL	$24.75 - $39.14 $2.77 Million - $4.38 Million	-111,936 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$29.0 - $41.62 $3.25 Million - $4.66 Million	111,936 New	111,936 $3.66 Million
Q3 2020 Nov 16, 2020	SELL	$16.3 - $30.64 $225,836 - $424,517	-13,855 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$7.95 - $18.81 $110,147 - $260,612	13,855 New	13,855 $225,000
Q4 2019 Feb 14, 2020	SELL	$12.97 - $15.94 $495,246 - $608,652	-38,184 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$14.75 - $20.87 $4.57 Million - $6.46 Million	-309,514 Reduced 89.02%	38,184 $579,000
Q2 2019 Aug 14, 2019	BUY	$14.71 - $19.79 $4.78 Million - $6.44 Million	325,258 Added 1449.46%	347,698 $6.85 Million
Q1 2019 May 14, 2019	BUY	$13.73 - $16.87 $308,101 - $378,562	22,440 New	22,440 $372,000
Q2 2018 Aug 14, 2018	SELL	$14.8 - $18.8 $162,800 - $206,800	-11,000 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$14.5 - $23.4 $159,500 - $257,399	11,000 New	11,000 $206,000

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $490M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.